Optimization of anti-cobratoxins for treatment of neurotoxic envenomings

Mireia Solà, Andreas H. Laustsen, Lars Olsen, Mads H. Clausen, Brian LohseTechnical 2015 · DOI

Introduction

Snakebite envenoming is a critical neglected tropical disease that causes significant mortality and morbidity worldwide. Among the most dangerous species are cobras (Naja spp.), whose venom contains potent "long $\alpha$-neurotoxins" known as cobratoxins. These toxins specifically target nicotinic acetylcholine receptors (nAChRs) at the neuromuscular junction. When these receptors are blocked, the victim suffers from progressive muscle paralysis, leading to respiratory arrest and death within 3 to 12 hours if left untreated.

The Challenge of Traditional Antivenoms

The current "gold standard" for treatment is the administration of antivenom produced by immunizing horses or sheep with snake venom. While effective, this traditional method has three major drawbacks:

  1. Immunogenicity: Because the antivenom consists of foreign equine or ovine antibodies, patients often suffer from severe side effects, including serum sickness or even fatal anaphylaxis.
  2. Cost and Complexity: Maintaining herds of animals and the subsequent purification process is laborious and expensive.
  3. Stability: Biological antivenoms often require a cold chain, which is difficult to maintain in the rural, tropical areas where snakebites are most common.

This research project aims to revolutionize treatment by moving away from animal-derived products toward synthetic peptide-based therapies.

Methodology and Peptide Discovery

The research follows a rigorous pipeline of discovery, validation, and optimization to create a "next-generation" antivenom. The team previously identified a "lead" peptide—a small chain of amino acids—that shows a high affinity for $\alpha$-cobratoxin using phage display selection. This technique involves screening a library of billions of different peptides to identify those that specifically bind to the toxin.

To validate and optimize this lead, the researchers utilized several biophysical and electrophysiological techniques:

  • Isothermal Titration Calorimetry (ITC): This technique was used to measure the binding affinity and thermodynamics between the peptide lead and the $\alpha$-cobratoxin, confirming that the peptide binds to the toxin in solution.
  • Two-Electrode Voltage Clamp (TEVC): To ensure the peptide is actually neutralizing the toxin, TEVC was used to measure the functional inhibition of the toxin’s effect on nAChRs. This proved the peptide can prevent the toxin from blocking the receptor in a biological context.
  • Peptide Optimization: The core of the current work involves designing and characterizing improved analogues of the original lead to increase binding strength and biological stability.

Key Insights: Peptides as Molecular Decoys

The fundamental strategy of this research is to create a synthetic molecule that acts as a decoy, mimicking the binding site of the human nAChR. By "tricking" the cobratoxin into binding to the peptide instead of the patient's nerves, the toxin is effectively neutralized before it can cause paralysis.

Because many cobra species utilize similar long $\alpha$-neurotoxins, a well-optimized peptide could potentially act as a broad-spectrum treatment effective against multiple species. Furthermore, moving to peptides allows for chemical synthesis, which is more scalable, produces a more consistent product, and eliminates the risk of animal-derived contaminants.

Results and Future Outlook

The researchers have successfully confirmed a peptide lead that binds $\alpha$-cobratoxin and proven its functional neutralization in controlled environments. They are currently characterizing a new generation of analogues intended to serve as the basis for a clinical antitoxin.

However, several hurdles remain before this can reach clinical application. The results discussed are primarily in vitro, and the next major challenge is proving these peptides remain stable and effective inside a living organism (in vivo). Future work must address pharmacokinetics—ensuring the peptide stays in the victim's system long enough to neutralize all circulating venom—and the potential need for a "cocktail" of peptides to address the full complexity of cobra venom, which contains other toxins like cytotoxins in addition to neurotoxins.

Summary updated

BibTeX
@inproceedings{sola2015optimization,
  author = {Mireia Solà and Andreas H. Laustsen and Lars Olsen and Mads H. Clausen and Brian Lohse},
  title = {{Optimization of anti-cobratoxins for treatment of neurotoxic envenomings}},
  booktitle = {Technical},
  year = {2015},
  doi = {10.13140/rg.2.2.10745.47206},
}
Figure